PDCD1 and hepatitis A virus infection: By blocking inhibitory pathways like PD-1 and CTLA-4, these therapies can lead to the loss of immune tolerance, causing the immune system to attack healthy tissues and resulting in conditions such as colitis, pneumonitis, and hepatitis.